Eloralintide vs Pramlintide
Pramlintide was the first amylin analogue, approved in 2005 as a mealtime adjunct in diabetes with a short half-life. Eloralintide is a modern long-acting, receptor-selective amylin agonist studied once weekly for body weight.
Eloralintide
Eloralintide (LY3841136) is an investigational, selective, long-acting amylin-receptor agonist.
BEST STUDIED FOR
Selective amylin-receptor metabolic research
R2 999View product →
Pramlintide
A synthetic analogue of the pancreatic hormone amylin, the first approved amylinomimetic.
BEST STUDIED FOR
Incretin & metabolic
Read the cited profile →
Side by side · to buy
Price, purity and dispatch
| Compare | Eloralintide15mg | Pramlintide |
|---|---|---|
| Price | R2,999 | — |
| Cost per mg | R200 / mg | — |
| Purity (Janoshik) | On request | — |
| Stock | Restocking | — |
| Dispatch | When restocked | — |
| Certificate | Request CoA | — |
| Literature | 4 papers → | — |
| Research focus | Selective amylin-receptor metabolic research | Incretin & metabolic |
| Notify me | Read the cited profile |
Prices are read live from the catalogue. Cost per mg is the vial price over its stated mg. Purity is shown only where the certificate is published. Every compound is supplied for laboratory research only.
SIDE BY SIDE
| Eloralintide | Pramlintide | |
|---|---|---|
| The key difference | Investigational, long-acting, weekly | Approved, short-acting, mealtime |
| Class | Incretin & metabolic | Incretin & metabolic |
| Mechanism | Eloralintide (LY3841136) is an investigational, selective, long-acting amylin-receptor agonist. | Amylin is co-secreted with insulin; it lowers post-meal glucose by suppressing glucagon, slowing gastric emptying and reducing food intake. |
| Status | Investigational selective amylin-receptor agonist (Eli Lilly); phase 2 published, phase 3 under way. Not approved anywhere. | Approved (2005, US) as an adjunct to mealtime insulin in type 1 and type 2 diabetes. The scientific ancestor of cagrilintide. |
| Reported safety signals | The phase 2 report describes the gastrointestinal tolerability profile expected of the amylin class; no long-term data. | Hypoglycaemia risk when combined with insulin is the key labelled concern; a randomised study found it could provoke migraine-like attacks in migraine patients. |
| A key study | Describes eloralintide’s discovery and pharmacology through to clinical proof of concept. (Mol Metab 2025, PMID 41109426) | Reviews pramlintide as the first amylinomimetic, approved in 2005 as an insulin adjunct. (Am J Health Syst Pharm 2005, PMID 16278328) |
WHEN TO RESEARCH WHICH
Pramlintide is the clinical reference for amylin pharmacology; eloralintide represents the long-acting, obesity-focused generation. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.
REFERENCES (PUBMED)
- [Eloralintide] Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept — Mol Metab 2025. PMID 41109426
- [Eloralintide] Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept — Diabetes Obes Metab 2026. PMID 41559929
- [Eloralintide] Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial — Lancet 2025. PMID 41207310
- [Pramlintide] Pramlintide acetate — Am J Health Syst Pharm 2005. PMID 16278328
- [Pramlintide] Pramlintide in the treatment of type 1 and type 2 diabetes mellitus — Clin Ther 2005. PMID 16330288
- [Pramlintide] Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients — Ann Neurol 2021. PMID 33772845
FREQUENTLY ASKED
What is the difference between Eloralintide and Pramlintide?
Pramlintide was the first amylin analogue, approved in 2005 as a mealtime adjunct in diabetes with a short half-life. Eloralintide is a modern long-acting, receptor-selective amylin agonist studied once weekly for body weight.
What is the regulatory status of Eloralintide and Pramlintide?
Eloralintide: Investigational selective amylin-receptor agonist (Eli Lilly); phase 2 published, phase 3 under way. Not approved anywhere. Pramlintide: Approved (2005, US) as an adjunct to mealtime insulin in type 1 and type 2 diabetes. The scientific ancestor of cagrilintide.
What safety signals have been reported?
Eloralintide: The phase 2 report describes the gastrointestinal tolerability profile expected of the amylin class; no long-term data. Pramlintide: Hypoglycaemia risk when combined with insulin is the key labelled concern; a randomised study found it could provoke migraine-like attacks in migraine patients.
Which studies is this comparison based on?
For Eloralintide: “Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept” (PMID 41109426); “Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept” (PMID 41559929); “Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial” (PMID 41207310). For Pramlintide: “Pramlintide acetate” (PMID 16278328); “Pramlintide in the treatment of type 1 and type 2 diabetes mellitus” (PMID 16330288); “Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients” (PMID 33772845).
MORE COMPARISONS
All products supplied for research purposes only. Not for human consumption.
In stock · ships from South Africa
In stock now
Supplied for laboratory research only · not for human use